Scarica l'app Stockscreener
23.94
1.44%
0.34
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché VKTX Giù?
Forum
Previsione
Precedente Chiudi:
$23.60
Aprire:
$22.04
Volume 24 ore:
5.02M
Relative Volume:
1.08
Capitalizzazione di mercato:
$2.76B
Reddito:
-
Utile/perdita netta:
$-99.15M
Rapporto P/E:
-25.74
EPS:
-0.93
Flusso di cassa netto:
$-74.25M
1 W Prestazione:
+11.25%
1M Prestazione:
-19.75%
6M Prestazione:
-62.95%
1 anno Prestazione:
-63.98%
Intervallo 1D:
$21.23
$24.12
Intervallo di 1 settimana:
$21.21
$27.09
Portata 52W:
$18.92
$81.86
Viking Therapeutics Inc Stock (VKTX) Company Profile
Nome
Viking Therapeutics Inc
Settore
Industria
Telefono
858-704-4660
Indirizzo
9920 PACIFIC HEIGHTS BLVD, SUITE 350, SAN DIEGO, CA
Confronta VKTX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VKTX
Viking Therapeutics Inc
|
23.94 | 2.76B | 0 | -99.15M | -74.25M | -0.93 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Viking Therapeutics Inc Stock (VKTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-08 | Iniziato | Goldman | Neutral |
| 2025-02-13 | Iniziato | Scotiabank | Sector Outperform |
| 2025-02-07 | Iniziato | Citigroup | Neutral |
| 2024-12-02 | Iniziato | Piper Sandler | Overweight |
| 2024-11-22 | Iniziato | B. Riley Securities | Buy |
| 2024-11-04 | Reiterato | H.C. Wainwright | Buy |
| 2024-09-11 | Iniziato | JP Morgan | Overweight |
| 2024-06-27 | Iniziato | Morgan Stanley | Overweight |
| 2024-05-16 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2024-03-26 | Reiterato | Oppenheimer | Outperform |
| 2024-03-07 | Iniziato | Jefferies | Buy |
| 2024-02-28 | Reiterato | Oppenheimer | Outperform |
| 2023-05-31 | Ripresa | ROTH MKM | Buy |
| 2023-03-28 | Reiterato | Maxim Group | Buy |
| 2023-03-17 | Iniziato | Stifel | Buy |
| 2021-07-29 | Ripresa | BTIG Research | Buy |
| 2021-05-25 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2020-06-05 | Iniziato | BMO Capital Markets | Outperform |
| 2020-05-05 | Iniziato | Chardan Capital Markets | Buy |
| 2020-05-01 | Iniziato | BTIG Research | Buy |
| 2019-07-16 | Iniziato | Oppenheimer | Outperform |
| 2019-06-25 | Iniziato | Stifel | Buy |
| 2019-03-29 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2019-03-14 | Reiterato | Maxim Group | Buy |
| 2019-02-22 | Iniziato | SVB Leerink | Mkt Perform |
| 2018-12-12 | Iniziato | B. Riley FBR | Buy |
| 2018-11-19 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2018-09-18 | Reiterato | H.C. Wainwright | Buy |
| 2018-09-18 | Reiterato | Maxim Group | Buy |
| 2018-09-18 | Reiterato | Raymond James | Outperform |
| 2018-07-20 | Iniziato | SunTrust | Buy |
| 2018-06-28 | Iniziato | Raymond James | Outperform |
| 2018-06-01 | Reiterato | Laidlaw | Buy |
| 2018-05-31 | Reiterato | Maxim Group | Buy |
| 2018-03-26 | Ripresa | H.C. Wainwright | Buy |
| 2017-11-28 | Reiterato | Maxim Group | Buy |
| 2017-11-21 | Iniziato | ROTH Capital | Buy |
Mostra tutto
Viking Therapeutics Inc Borsa (VKTX) Ultime notizie
Viking Therapeutics (NasdaqCM:VKTX) Completes Enrollment For Phase 2 Trial Of VK2735 - Yahoo Finance
H.C. Wainwright still expects Viking to ‘differentiate’ after Lilly data - Yahoo Finance
JPMorgan says Lilly data ‘highly favorable’ for Structure Therapeutics - Yahoo Finance
Viking Therapeutics, Inc. (VKTX) Beats Stock Market Upswing: What Investors Need to Know - Yahoo Finance
Why Eli Lilly Stock Is Soaring Today, While Novo Nordisk and Viking Therapeutics Slide - Yahoo Finance
Viking Therapeutics (VKTX) Gains Attention with Promising Diabetes Treatment | LLY Stock News - GuruFocus
2 Stocks Down by 25% or More This Year to Buy and Hold - Yahoo Finance
Viking Therapeutics: A Lot More Compelling After The MeltdownInitiating Cautious Buy (Rating Upgrade) - Seeking Alpha
Viking Therapeutics (VKTX) Shares Surge on Pfizer's Decision - GuruFocus
Viking Therapeutics (VKTX) to Announce Q1 2025 Financial Results - GuruFocus
Viking Therapeutics Inc (VKTX) Stock Price, Trades & News - GuruFocus
Viking Therapeutics (VKTX) Shares Decline Following Eli Lilly's Phase 3 Results | LLY Stock News - GuruFocus
Viking Therapeutics slips after Eli Lilly reports orforglipron trial results - TipRanks
Viking Therapeutics to Report Financial Results for First Quarter 2025 on April 23, 2025 - Quantisnow
Viking Therapeutics to Report Financial Results for First Quarte - GuruFocus
Viking Therapeutics Sets Q1 Earnings Date: Key Updates Expected on Metabolic Drug Pipeline - Stock Titan
Viking Therapeutics Stock Pops But Struggles to Hold Gains - MarketBeat
Viking Therapeutics Stock Pops But Struggles To Hold Gains - Barchart.com
Viking Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:VKTX - Benzinga
Viking Therapeutics: Trading The Volatility Of The Weight Loss Drug Market - Seeking Alpha
Will Pfizer approach Viking Therapeutics with a buyout proposal? - TradingView
Viking Therapeutics' VK2735 Candidate Likely Boosted By Pfizer's Woes (NASDAQ:VKTX) - Seeking Alpha
Down 71%, Should You Buy the Dip on Viking Therapeutics Stock? - MSN
NVO, LLY, GPCR & VKTX Stocks Gain Following PFE's Obesity Study Setback - Zacks Investment Research
Viking Therapeutics (VKTX) Surges as Pfizer Halts Obesity Drug - GuruFocus
Why Viking Therapeutics, Inc. (VKTX) Skyrocketed On Monday? - MSN
Director Foehr Matthew W exercised 20,786 shares at a strike of $8.00, increasing direct ownership by 19% to 132,036 units (SEC Form 4) - Quantisnow
Pfizer Abandons Obesity Pill After Liver Injury in Setback - Bloomberg.com
Why Eli Lilly, Novo Nordisk, and Viking Therapeutics Stocks All Popped Today - The Globe and Mail
Pfizer's $130B Weight-Loss Dream Just Collapsed - Yahoo Finance
Viking stock on a tear after Pfizer setback (VKTX:NASDAQ) - Seeking Alpha
What's Going On With Viking Therapeutics, Structure Therapeutics Stock On Monday? - Benzinga
Biotech Stock A Big Winner After Pfizer Halts Weight-Loss Drug - Schaeffer's Investment Research
Viking Therapeutics shares surge on Pfizer’s drug discontinuation By Investing.com - Investing.com India
Viking Therapeutics shares surge on Pfizer’s drug discontinuation - Investing.com
3 Magnificent Stocks That Could Double or More by 2030 - Yahoo Finance
Will Viking Therapeutics Be a Top Healthcare Stock in 10 Years? - Yahoo
Viking Therapeutics stock hits 52-week low at $20.26 - Investing.com Australia
Viking Therapeutics stock hits 52-week low at $20.26 By Investing.com - Investing.com South Africa
Goldman Sachs Initiates Coverage of Viking Therapeutics (VKTX) with Neutral Recommendation - Nasdaq
Amendment: Director Rouan Sarah Kathryn bought $29,943 worth of shares (1,240 units at $24.15) (SEC Form 4) - Quantisnow
Goldman Sachs Initiates Coverage on Viking Therapeutics (VKTX) w - GuruFocus
Viking Therapeutics draws Neutral rating at Goldman Sachs on competitive headwinds - Seeking Alpha
Goldman initiated coverage on Viking Therapeutics with a new price target - Quantisnow
Goldman Sachs Initiates Viking Therapeutics With Neutral Rating, $30 Price Target - MarketScreener
Goldman Sachs sets Viking Therapeutics stock at Neutral By Investing.com - Investing.com Canada
The Smartest Biotech Stocks to Buy With $50 - AOL.com
When the Price of (VKTX) Talks, People Listen - news.stocktradersdaily.com
Viking Therapeutics to Participate at Morgan Stanley 22nd Annual Global Healthcare Conference - Quantisnow
Viking therapeutics director Rouan buys $29,942 in stock By Investing.com - Investing.com Canada
Viking therapeutics director Rouan buys $29,942 in stock - Investing.com India
Viking Therapeutics Inc Azioni (VKTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.51%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):